Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years
By Dominic Chopping
Novo Nordisk aims to launch several new blockbuster drugs in the next few years while expanding into further treatment areas, part of a new plan to revive growth that the Ozempic manufacturer outlined at an investor event in London on Monday.
In addition to at least five new "multiblockbusters," the company is aiming to have at least five new obesity and diabetes drugs and a similar number of drugs in other therapeutic areas in late stage trials by 2030.
It also targets the delivery of over 150 billion Danish kroner ($23.05 billion) in sales from its pipeline drugs in 2035. The company's 2025 total sales were 309.06 billion kroner.
Speaking at the event, Chief Executive Mike Doustdar said that while the company will continue to strengthen its diabetes portfolio and expand the obesity pipeline, "It's also time to further diversify the company."
Novo Nordisk will seek to build out future growth areas in blood and endocrine disorders, liver diseases, and cardiovascular diseases, Doustdar said.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 21, 2026 04:52 ET (08:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States